Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is advancing the development of its lead oncology candidate, ONC010, a PNKP inhibitor designed to disrupt cancer cells’ DNA repair mechanisms and potentially address treatment resistance. The company recently achieved a key milestone by advancing kilogram-scale manufacturing of a crucial precursor used to produce ONC010’s active pharmaceutical ingredient. This development supports future formulation development, Good Manufacturing Practice (GMP) production, and clinical studies.
The company also signed a letter of intent with Nanosoft Polymers to collaborate on polymer development, drug delivery optimization, and formulation work. Additionally, engagements with Nucro-Technics and Avance Clinical are supporting bioanalytical development and clinical and regulatory planning. These collaborative efforts reflect Onco-Innovations’ broader strategy to build the necessary manufacturing, formulation, and clinical infrastructure to advance ONC010 toward future first-in-human studies.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. It has secured an exclusive worldwide license to patented technology that targets solid tumors. For more information, visit the company’s website at https://oncoinnovations.com/.
The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF.
This announcement highlights Onco-Innovations’ progress in building a robust pipeline and infrastructure for its lead candidate, positioning the company to potentially address treatment resistance in oncology. The advancements in manufacturing and partnerships are critical steps toward clinical evaluation.
